Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers

Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. A case-control study including all cases of recurrent s...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2019-06, Vol.153 (3), p.517-520
Main Authors: Moroney, Marisa R., Davies, Kurtis D., Wilberger, Adam C., Sheeder, Jeanelle, Post, Miriam D., Berning, Amber A., Fisher, Christine, Lefkowits, Carolyn, Guntupalli, Saketh R., Behbakht, Kian, Corr, Bradley R.
Format: Article
Language:English
Subjects:
Adult
Aged
beta Catenin - genetics
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Endometrioid - genetics
Carcinoma, Endometrioid - pathology
Case-Control Studies
Class I Phosphatidylinositol 3-Kinases - genetics
DNA Polymerase II - genetics
Endometrial cancer
Endometrial Neoplasms - genetics
Endometrial Neoplasms - pathology
Female
Humans
Membrane Proteins - genetics
Microsatellite Instability
Middle Aged
Molecular testing
Mutation
Neoplasm Grading
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Poly-ADP-Ribose Binding Proteins - genetics
PTEN Phosphohydrolase - genetics
Risk-stratification
Tumor Suppressor Protein p53 - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Cases were matched to controls by age, BMI, weight and stage. Molecular testing and immunohistochemistry were performed on archival tumor specimens: microsatellite instability (MSI-H), mismatch repair status, POLE mutational status, and next-generation sequencing. 15 stage I, grade 1 endometrial cancer cases with recurrent disease and available tumor specimens were identified. CTNNB1 and MSI-H were present at significantly higher rates in cases than controls (CTNNB1 60% vs. 28%, OR 3.9, 95%CI 1.1–14.7, p = 0.04 and MSI-H 53% vs. 21%, OR 4.4, 95%CI 1.1–17.0, p = 0.03). POLE mutations were found in 0% of cases vs. 7% of controls (p = 0.54). Among specimens demonstrating microsatellite stability (MSS), 100% of cases vs. 26% of controls had CTNNB1 mutations (p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2019.03.100